Cellect Biotechnology Ltd. (NASDAQ:APOP) traded -51.56% off of the 52-week high price. On the other end, company shares have been noted 6.86% away from the low price over the last 52-weeks. 52 week range of the stock remained $ 6.12 – 13.50. Switching over to some distances from popular moving averages, we see that the stock has been recorded -12.33% away from the 50 day moving average and -16.13% away from the 200 day moving average. Moving closer, we can see that shares have been trading -5.59% off of the 20-day moving average.
Cellect Biotechnology Ltd. (NASDAQ:APOP), a developer of a novel stem cell enabling technology, declared that it has successfully completed the proof of concept testing of its first in type new product prototype, ApoTainer™ using Cellect’s FasL-coated magnetic beads for maximizing efficacy and scalability of stem cell based products’ manufacturing. The ApoTainer™ is designed to replace highly complex and expensive procedures currently used by laboratories (e.g. Bone marrow transplantations), with a significantly more effective process at a fraction of the time and cost.
The Company believes the ApoTainer™ represents a breakthrough in achieving commercial grade scalability with a solution suitable for a wide range of users from large pharma companies interested in cost effective stem cell production through hospitals and clinics to small research laboratories. Pre-clinical proof of concept testing of Cellect’s proprietary ApoTainer™ has shown that the use of FasL-coated magnetic beads significantly increases the active surface allowing a dramatic increase of interactions between the selecting agent and the cells. The testing showed that the prototype increases specific elimination of certain (but not all) of the non-stem cells while full preservation of the number and function of the stem and progenitor cells.
Utilizing the ApoTainer™, Cellect expects blood stem cell donation to be transplantable within less than 6 hours from donation through a simple process performed at the hospital bedside instead of undergoing a lengthy laboratory procedure in a highly specialized setting. The standard medical procedure for reaching enriched stem cells currently costs tens of thousands of dollars and produces significant adverse effects.
ApoTainer™-based blood stem cell transplantation is being designed to result in improved recovery of the patient’s immune system with significant reduction of safety concerns in contrast to the significant morbidity or even death caused by the standard medical procedure. Reducing the procedure related adverse effects is anticipated to cause a significant increase in the number of bone marrow transplantations – the only stem cell based medical procedure fully accepted by the medical community.
Cellect Biotechnology Ltd. (NASDAQ:APOP) closed with change of 0.00% to $6.54 with the total traded volume of 13873 shares versus to an average volume of 46.11K. The stock was up in the 5 days activity 2.51%. The one month performance of stock was -12.57%. APOP shares are -33.33% for the quarter and driving a -29.37% over the course of the past year and is now -6.57% since this point in 2018. The average volatility for the week and month was at 4.36% 4.01% respectively.